| Date | Title | Description | |
|---|---|---|---|
| 10 May 2023 | On P&L | The Company releases the first quarter 2023 financial results presentation | Download |
| 10 May 2023 | On P&L | The Company releases the press release related to the first quarter 2023 financial results | Download |
| 25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
| 21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
| 21 Feb 2023 | On business and financial situation | The Company releases the press release related to the full year 2022 financial results. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 31 Jul 2024 | Liquidity and counterparty agreements | Modification of securities and cash balances associated with the Liquidity Contract signed between the Company and Bestinver, S.V., S.A. | Download |
| 08 Jul 2024 | Other relevant information | The Company informs about the dividends payment. | Download |
| 04 Jul 2024 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2024 | Download |
| 24 Jun 2024 | Announcement of General Shareholders' Meeting | The Company reports on the resolutions adopted by the Ordinary General Shareholders' Meeting and by the Board of Directors. | Download |
| 11 Jun 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 7 June 2024 and 11 June 2024 and end of the share buyback program | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 05 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. | Download |
| 03 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted from 11 July to 30 September 2017 | Download |
| 07 Sep 2017 | Otros sobre negocio y situación financiera | The Company informs that commences the enoxaparin biosimilar marketing in Germany | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |